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ABSTRACT 
 
Background: Ischemic stroke and coronary heart disease are important contributors to the global 
disease burden and share atherosclerosis as the main underlying cause. Recent evidence from a 
genome-wide association study (GWAS) suggested that single nucleotide polymorphisms (SNP) near 
the MMP12 gene at chromosome 11q22.3 were associated with large-vessel ischemic stroke. Here we 
evaluated and extended these results by examining the relationship between MMP12 and 
atherosclerosis in clinical and experimental studies.    
Methods and Results: Plasma concentrations of MMP-12 were measured at baseline in 3 394 
subjects with high-risk for cardiovascular disease (CVD) using the Olink ProSeek CVD I array. The 
plasma MMP-12 concentration showed association with incident cardiovascular and cerebrovascular 
events (130 and 67 events respectively over 36 months) and carotid intima-media thickness 
progression (p=3.6x10-5). A GWAS of plasma MMP-12 concentrations revealed that SNPs rs499459, 
rs613084 and rs1892971 at chr11q22.3 were independently associated with plasma MMP-12 (p<5x10
-
8). The lead SNPs showed associations with mRNA levels of MMP-12 and adjacent MMPs in 
atherosclerotic plaques. MMP-12 transcriptomic and proteomic levels were strongly significantly 
increased in carotid plaques compared with control arterial tissue and in plaques from symptomatic vs. 
asymptomatic patients. By combining immunohistochemistry and proximity ligation assay, we 
demonstrated that MMP-12 localises to CD68+ macrophages and interacts with elastin in plaques. 
MMP-12 silencing in human THP-1 derived macrophages resulted in reduced macrophage migration. 
Conclusions: Our study supports the notion that MMP12 is implicated in large-artery atherosclerotic 
stroke, functionally by enhancing elastin degradation and macrophage invasion in plaques. 
 
Key words: atherosclerosis, carotid intima-media thickness, matrix metalloproteinase, plaque rupture, 
stroke, vascular disease 
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INTRODUCTION 
 
Atherosclerosis is a major cause of coronary heart disease (CHD) and along with cardioembolism 
contributes significantly to ischemic stroke (IS). The disease involves gradual accumulation of lipids 
and inflammatory cells encapsulated by fibrotic tissue in the intima of larger arteries [1]. Erosion or 
rupture of the fibrous cap covering the atherosclerotic plaque exposes plaque content to circulating 
blood and triggers thrombosis that may lead to myocardial infarction (MI) and stroke. The more 
recent view of plaque rupture and erosion suggests that atherosclerotic lesions undergo circles of 
remodelling, involving both stabilisation and destabilisation events, rather than being gradually 
weakened in a continuous manner [2].  
Plaque remodelling involves breakdown of extracellular matrix (ECM), which is a process partly 
controlled by matrix metalloproteinases (MMPs), a family of 20 secreted or membrane-associated 
endoproteinases and their inhibitors [3, 4]. Evidence for a role of MMPs in cardiovascular disease 
(CVD) has been obtained from studies in transgenic disease models and in studies investigating some 
MMPs as biomarkers for clinical events [5-10]. In contrast, few studies have evaluated the role of 
MMPs in CVD using human genetics integrated with mRNA and protein expression in carotid tissue. 
Robust genetic association between the MMP gene cluster (chromosome 11q22.3) and large artery 
stroke was recently demonstrated in genome-wide association study (GWAS) (13). In addition, 
association between SNPs at the 11q22.3 locus and COPD has been demonstrated [11-13]. The lead 
SNP for large-artery stroke, rs660599, is located near the MMP12 gene and it was shown that the 
MMP-12 mRNA expression in disease tissue is increased compared to healthy controls, which 
suggested that MMP-12 drives the genetic association signal for stroke observed at 11q22.3 [13].  
It is well established that identification of the causal gene of GWAS loci is challenging, mainly due to 
high degree of linkage disequilibrium across large regions of the genome but also because distal 
genomic regulation of genes is common. The 11q22.3 region is no exception as it harbours several 
other members of the MMP family (MMP7, MMP20, MMP8, MMP10, MMP1, MMP3 and MMP13), 
of which many have been suggested to play a role in atherosclerosis. Therefore, additional evidence is 
required to establish the role of MMP-12 in large-artery stroke. To address this question, we applied 
an integrative approach and investigated MMP-12 protein and gene variants in relation to carotid 
intima-media thickness (cIMT) progression, incident CVD, transcriptomic and proteomic levels in 
carotid plaque tissue, followed-up with detailed in situ and in vitro studies (design shown in Fig. 1).  
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MATERIAL AND METHODS 
 
The IMPROVE study 
The IMPROVE study is a multicentre, longitudinal, observational study, which recruited 3 711 
subjects with at least three cardiovascular risk factors but who were asymptomatic for CVD. Subjects 
were recruited from Finland, France, Italy, the Netherlands, and Sweden. Detailed cIMT 
measurements were performed at baseline, after 15 months and at 30 months. The Fastest-IMTmax-progr 
parameter, herein referred to as cIMT progression, was previously developed and evaluated in the 
IMPROVE study and found to independently predict new CVD events [14]. Incident CVD end points 
were defined as occurrence of myocardial infarction, angioplasty, diagnosis of angina pectoris, 
angioplasty, coronary artery bypass grafting and/or sudden cardiac death, ischemic stroke, transient 
ischemic attack, peripheral revascularization, and/or diagnosis of intermittent claudication during a 
median follow-up of 36 months. Further design features and definitions of the study are described in 
the online supplement and in previously published articles [14, 15]. 
Plasma MMP-12 concentrations were measured at baseline using the Olink ProSeek CVD array I 
(Olink Proteomics, Uppsala, Sweden), according to the standard protocol [16]. The inter-plate 
coefficient of variation for the MMP-12 assay was 14 %, as estimated using a pooled plasma control 
across all plates. The measurements were carried out in 3 394 IMPROVE participants in whom 
genotype information post quality control (QC) was also present. Plasma MMP-12 activity was 
measured in duplicates in 20 plasma samples from the IMPROVE cohort. Ten samples were randomly 
chosen from the 75-95
th
 percentile of plasma MMP-12 concentration and ten from the 5-25
th 
percentile.  Activity was measured with the Fluorimetric Sensolyte 520 MMP-12 Assay Kit 
(Anaspec), which specifically detects elastin degradation products (desmosin). 
Genotyping in the IMPROVE study was performed using the Illumina CardioMetabochip and the 
Immunochip arrays [17, 18]. The combined SNP genotyping data on both platforms were merged and 
subjected to the following QC using PLINK 1.7, standard programming tools and manual proof-
reading. SNPs were excluded for probe to genome mismatch, incorrect assignment of allelic variants 
in the array design, failed Hardy-Weinberg Equilibrium test at 1x10-6, call rate <95% or failed 
Illumina genotype calling QC. Samples were excluded that showed evidence of gender mismatch, 
abnormal inbreeding coefficient, failed cryptic relatedness test or had an overall sample call rate 
<95%. After QC and filtering out of SNPs with a minor allele frequency of <0.5%, a total number of 
260 484 unique SNPs in 3 403 subjects remained for analysis. 
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The BiKE study 
Patients undergoing surgery for symptomatic (S) or asymptomatic (AS), high-grade (>50% NASCET) 
carotid stenosis at the Department of Vascular Surgery, Karolinska University Hospital, Sweden were 
consecutively enrolled in the study and clinical data recorded on admission [19]. Symptoms of plaque 
instability were defined as transitory ischemic attack (TIA), minor stroke (MS) and amaurosis fugax 
(retinal TIA; AF). Patients without qualifying symptoms within 6 months prior to surgery were 
categorised as AS and indication for carotid endarterectomy based on results from the Asymptomatic 
Carotid Surgery Trial (ACST) [20]. Carotid endarterectomies (carotid plaques, CP) and blood samples 
were collected at surgery and retained within the Biobank of Karolinska Endarterectomies (BiKE). 
This study involved 3 non-overlapping sub-cohorts of patients, where one Affymetrix microarray 
dataset was generated by profiling n=127 atherosclerotic plaques (of which n=87 were from S+40 
from AS patients) and n=10 normal arteries (further referred to as the ‘large dataset’) and the other by 
profiling n=50 plaques (n=40 from S+10 from AS patients) and n=5 normal arteries (further referred 
as the ‘small dataset’). DNA genotyping by Illumina chips was carried out on patients from the ‘large’ 
sub-cohort, and used for expression quantitative trait loci (eQTL) analyses. The third sub-cohort of 
n=18 BiKE plaques (n=9 from S+9 from AS patients, matched for gender, age and statin medication) 
were analysed using LC-MS/MS as previously described [21]. For these proteomic analyses, a central 
portion of the plaque corresponding to the maximum stenosis was separated from the respective 
downstream peripheral end (adjacent tissue) of the plaque and used in comparisons [22, 23]. Details 
of patient demographics, sample processing, microarray and proteomic analyses have been described 
previously and the study was approved by the regional Ethics Committee [24-27].  
In this study CHD [28] was defined as stable and unstable angina, nonfatal MI and coronary death and 
large artery stroke as thrombosis or embolism due to atherosclerosis of a large artery (internal carotid-
, middle cerebral-, vertebral- or basilar arteries) [29]. The study cohorts and workflow are presented in 
Fig. 1.  
 
Statistical analyses 
Association between plasma MMP concentrations, SNPs and cIMT at baseline and progression 
(fastest-IMTmax-progr) and incident CVD were tested using linear or logistic regression models with one 
basic model adjusting for recruitment centre, age, gender and another advanced model including also 
Framingham risk score parameters i.e. smoking, diabetes, systolic blood pressure, HDL-C and total 
cholesterol. Survival analysis of plasma MMP-12 tertiles was performed using Cox-regression. A 
total number of 67 cerebrovascular and 130 coronary endpoints were observed after 36 months in the 
subset of 3 394 IMPROVE subjects with complete baseline clinical data, genetic information and 
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plasma MMP-12 measurements. A total of 260 484 SNPs from the combined Illumina Immunochip 
and Metabochip genotyping arrays were tested as determinants for plasma MMP-12 using the Plink 
1.9 Wald-test of residuals derived from a linear regression model that adjusted for recruitment centre, 
age, gender, smoking, diabetes, hypertension, BMI and Olink ProSeek analysis batch [30]. The 
standard p-value threshold for genome-wide significance at 5x10-8 was used in the discovery of novel 
SNPs linked to plasma MMP-12 concentrations. Microarray and proteomic dataset analyses of BiKE 
samples were performed as reported previously [21, 24]. Correlation between mRNA or protein levels 
was assessed using Spearman whereas ANOVA was used for multi-group comparisons, with p<0.05 
as threshold for statistical significance. In the in vitro studies, cells were automatically counted using 
the “Cell Counter” plugin of the ImageJ software. Differences between the groups were tested using 
Student’s t-test.  
Additional methods are available in the online Supplemental Material. 
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RESULTS 
 
Plasma MMP-12 levels associate with cIMT progression and incident cardiovascular events 
MMP-12 plasma concentrations were positively correlated with age, smoking and diabetes and 
inversely with HDL-C in the IMPROVE study (Table 1), whereas no or weak correlations were 
observed with gender, systolic blood pressure or total cholesterol. Plasma MMP-12 at baseline was 
tested as potential predictor of cIMT both at baseline and in progression, using a basic model and an 
advanced model with additional adjustment for Framingham risk score baseline parameters. As 
previously shown by Goncalves et al [10], plasma MMP-12 was associated with cIMT at baseline, 
with the average thickness across all measured segments showing the strongest association (Table 2). 
The plasma MMP-12 concentration was also positively associated with faster cIMT progression, 
which persisted after adjustment for Framingham score parameters (Table 3). The association between 
plasma MMP-12 concentration and cIMT progression persisted even after additional adjustment for 
IMTmax at baseline (standardized beta=0.052, p=0.008). Plasma MMP-12 levels were also associated 
with incident CVD at 36 months (n=197) after adjustment for study site, age and gender (odds ratio 
1.26, 95% confidence interval (1.03-1.55), p=0.028). The odds ratio for cerebrovascular events (n=67) 
was 1.45, 95% confidence interval (1.03-2.05), p=0.034. After adjustment for Framingham risk score 
parameters, associations with both all CVD events and with cerebrovascular events only were 
attenuated (odds ratio 1.13, 95% confidence interval (0.91-1.40), p=0.26 and odds ratio 1.25, 95% 
confidence interval (0.87-1.81), p=0.22, respectively). A survival analysis of plasma MMP-12 tertiles 
suggested that patients in the highest tertile progressed more rapidly to cerebrovascular endpoints 
compared to the middle and lowest tertile (Cox-regression p=0.022, Supplementary Fig I) After 
adjustment for covariates, the association was no longer significant (p=0.15).  
Of note, MMP-1, MMP-3, MMP-7 and MMP-10 (present on the Olink CVD I assay) were also tested 
for association with cIMT at baseline, cIMT progression and incident CV events, but did not pass 
significance levels. 
 
SNPs at 11q22.3 and plasma MMP-12 concentrations 
Next, we aimed to assess whether SNPs at 11q22.3 were linked to plasma MMP-12 concentration 
using the IMPROVE study. Of a total number of 260 484 SNPs, 12 SNPs exceeded the standard 
threshold for genome-wide significance at 5x10
-8
 for association with plasma MMP-12 concentration 
(Supplementary Fig II). All associated variants mapped to the MMP gene cluster region on 
chromosome 11q22.3. SNP rs660599, previously associated with risk of stroke in the 
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METASTROKE study by Traylor et al (13), was associated with plasma MMP-12 at p=8.8x10-35. To 
identify potential additional association signals at this locus, conditional analyses were performed by 
adding the lead variant as covariate in linear regression models of adjusted plasma MMP-12. After 
three rounds of conditioning, including in order rs499459, rs1892971 and rs613804, no association 
signal at 5x10-8 remained (Supplementary Table I).  The r2 measure for linkage disequilibrium (LD) 
was less than 0.01 for any combination of these SNPs, suggesting that the effects of rs499459, 
rs1892971 and rs613804 on plasma MMP-12 concentration are independent from one another 
(Supplementary Table II). Finally, for the 3 variants emerging from IMPROVE analyses (rs499459, 
rs1892971 and rs613804) and the 1 from METASTROKE study (rs660599), we also stratified the 
association with plasma MMP-12 levels, mean and max cIMT and plaque area by each allele 
(Supplementary Table III). Interestingly, our results show that the A allele of rs660599, which was 
previously associated with stroke risk in the METASTROKE study, here associated with higher cIMT 
for the different intima-media measures, however the same allele also associated with lower plasma 
MMP-12 concentration. Similarly, the A allele of rs499459 associated with higher cIMT 
measurements and lower plasma MMP-12 levels.  
 
SNPs in the MMP12 region affect its mRNA expression in atherosclerotic plaque tissue  
In order to evaluate potential associations of SNPs rs499459, rs613804, and rs1892971 with plaque 
MMP-12 mRNA levels in patients with carotid atherosclerosis, eQTL analyses were performed using 
microarray data from the BiKE cohort. A tentative association was found for rs1892971 with MMP-
12 mRNA levels in plaques (p=0.079) (Fig. 2A). To investigate whether the effect of rs1892971 was 
specific for MMP12 or related also to adjacent genes in the MMP gene cluster, we tested its 
association with expression of MMP1, MMP3 and MMP13 in plaques, but no significance could be 
shown (Fig. 2A). A proxy for rs499459 (rs566125, r
2
=0.92; D’=1) showed no association with 
MMP12 plaque expression in the whole cohort, but when the association was stratified according to 
the patient phenotype, this variant showed significance particularly in plaques from asymptomatic 
patients (Supplementary Fig III). However, it was also significantly associated with expression of 
MMP1, MMP3 and marginally with MMP13 (p=0.00048, p=0.02 and p=0.045, respectively, Fig. 2B). 
No significance was obtained by similar eQTL analyses for rs613804. In addition, we sought to 
evaluate whether the reported lead SNP for large-artery atherosclerotic stroke, rs660599, was also 
related to MMP12 expression levels in plaques. A perfect proxy for rs660599, rs615098 (R2=1, D’=1) 
showed association with MMP12 mRNA expression in plaques generally (p=0.0039), as well as in 
plaques from asymptomatic patients (p=0.005) and symptomatic ones (p=0.049) separately 
(Supplementary Fig III). Interestingly, this variant also showed strong associations with both MMP1 
and MMP3 levels in plaques (p=0.0016 and p=0.0025, respectively, Fig. 2C). Other MMPs in this 
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region (MMP7, MMP8, MMP10, MMP20 and MMP27) were also examined for association with these 
variants, but showed no significance.  
Further analysis of LD in the associated genomic region using the SNIPA tool [31] with data from the 
European part of the 1000 genomes project, showed that rs499459 is located in a broader region of 
high LD with multiple other SNPs (including the lead SNP for stroke rs660599), that span MMP1, 
MMP3 and MMP12. In contrast, rs613804 is located in a region of high LD near and some distance 
downstream of the MMP12 gene. SNP rs1892971 (and those in high LD) is located in a narrow 
intergenic region upstream of MMP12 and downstream of MMP13 (Supplementary Fig IV).  
Of note, MMP-12 mRNA expression levels found in plaques from these eQTL analyses, were several 
fold higher than levels of any other interrogated MMP in this region.   
 
MMP12 is highly elevated in carotid plaques from symptomatic patients 
Indeed, on the transcriptomic level we observed strong upregulation of the MMP-12 mRNA 
expression in two independent microarray datasets comparing plaques vs. normal arteries (Fig. 3A). 
In the large dataset, the difference between these groups was log mean±SD=8.14±0.17, p<0.0001 
whilst in the smaller dataset it was log mean±SD=5.20±0.22, p<0.0001. Further upregulation was 
noted by stratifying patients into symptomatic vs. asymptomatic category (large dataset log 
mean±SD=0.74±0.33, p=0.03), and a trend towards upregulation in symptomatic patients was noted 
also in the smaller dataset (not shown). A strong enrichment of MMP-12 was confirmed on the 
proteomic level, with mean difference ±SD=0.90±0.10, p=0.04 comparing central plaques vs. adjacent 
tissue and mean difference±SD=1.00±0.07, p=0.03 by comparing plaques from symptomatic vs. 
asymptomatic patients (Fig. 3A).  
To evaluate the previous publications reporting high expression of MMP-12 in macrophages [32-35], 
we next investigated the correlation between MMP-12 expression and macrophage cell markers in 
plaques (Fig. 3B). MMP-12 transcript was strongly significantly correlated with that of macrophage 
markers CD163 (Spearman r=0.67, p<0.0001), CD36 (r=0.81, p<0.0001) and MAC2 (r=0.72, 
p<0.0001), and similarly positive significant correlations of MMP-12 with macrophage markers were 
confirmed on the protein level. 
 
MMP-12 localizes to macrophages and interacts with elastin in plaques 
In continuation, we sought to trace the MMP-12 protein and its major substrate elastin in human 
carotid arteries by immunohistochemistry. No signal for MMP-12 was present in a normal artery 
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whereas elastin was abundantly expressed in the media, as expected (Fig. 4A, arrows). In plaques we 
localized total MMP-12 mostly to macrophage-rich regions in the necrotic core by co-staining with an 
antibody against macrophage marker CD68 (Fig. 4B, third panel, arrows and Supplementary Fig VA). 
We also detected preserved, orderly packed elastin fibres sub-intimally at the plaque periphery, where 
no MMP-12 was expressed (Fig. 4B, second panel, arrows). However, towards the necrotic core, 
staining for elastin appeared gradually disarranged and co-localized with MMP-12 (Fig. 4B, second 
panel, enlarged inset), and was lost in consecutive sections of areas near the fibrous cap with 
condensed MMP-12
+
 macrophages (Supplementary Fig VA, enlarged insets). Signal for active MMP-
12 was observed diffusely in the extracellular matrix in the lesions, where elastin fibres were 
disarranged or absent (Supplementary Fig VB, arrows). Furthermore, by proximity ligation assay 
(PLA) we showed that MMP-12 and elastin proteins co-interact in plaques in situ, particularly in 
regions with moderate to strong MMP-12 expression (Fig. 4C, enlarged insets). 
 
MMP-12 levels correlate with elastin breakdown in plasma and plaques from atherosclerotic 
patients 
We also assessed the relationship between MMP-12 concentration and elastin degradation in plasma 
from the IMPROVE cohort, by measuring the level of the released degradation product desmosin. 
With equal elastin substrate amount available, we observed on average a 22% elevated elastin 
degradation in plasma samples with high MMP-12 levels compared to those with low MMP-12 levels 
(mean 56.1±5.84 vs. 46.0±9.20 µM desmosin, p=0.15, Supplementary Fig VIA). Similarly, in plaques 
we observed a strongly significant inverse correlation between MMP-12 and elastin protein levels (r= 
-0.47, p=0.004, Supplementary Fig VIB). Together with immunostainings for active MMP-12 in 
plaques, our results confirm an association between higher MMP-12 levels and increased elastolytic 
activity both in plasma and plaques from atherosclerotic patients.  
 
MMP-12 silencing leads to reduced macrophage recruitment and ECM invasion capacity  
In vitro experiments were performed to evaluate the previous studies suggesting that MMP-12 
influences macrophage migration and degradation of ECM proteins [34]. MMP-12 mRNA expression 
in THP-1 derived human macrophages was effectively inhibited by siRNA and the reduction was 
estimated to 70% by qPCR analysis (Supplementary Fig VII). Western blot demonstrated that MMP-
12 mRNA downregulation was associated with ~25% reduction in active MMP-12 protein in 
macrophages (Supplementary Fig VII). Our results showed that macrophages with reduced MMP-12 
levels exhibited ~30% lower invasion capacity compared to controls (%invasion=45±13 vs. 64.5±12, 
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p=0.01). We then examined the macrophage invasion capacity upon lowering of the MMP-12 
availability with an MMP-12-specific antibody, in both the control and the silenced cells. MMP-12 
inhibition by antibody blocking resulted in ~31% less macrophage invasion compared to controls 
(%invasion=16.5±4.2 vs. 23.9±5.2, p=0.04). Furthermore, we observed a reduction in the total 
number of macrophages invading through the ECM once the antibody was introduced. The mean 
reduction was 63%, p=0.02 for cells with suppressed MMP-12 levels and 62%, p=0.02 for those with 
normal MMP-12 levels (Fig. 5A).  
In addition, we sought to identify whether MMP-12 expression levels in macrophages affected the 
recruitment of other macrophages. We observed that the migration of new macrophages was 20% 
lower towards macrophages with reduced MMP-12 expression. Post migration, 28.5% 
(mean=430.5±27 cells) of the total cell count in the Transwell chamber originated from macrophages 
that migrated towards those with suppressed MMP-12, whereas 35.4% (mean=743.5±81 cells) 
originated from the population of macrophages that had migrated towards those with unchanged 
MMP-12 expression (p=0.01, Fig. 5B). 
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DISCUSSION 
 
We used an integrative approach based on genetics, transcriptomics and proteomics in clinical and 
experimental samples to demonstrate that i) MMP-12 is regulated at the mRNA and protein level by 
SNPs in the MMP gene cluster, ii) its plasma concentration is linked to cIMT progression as well as 
cerebrovascular events in high-risk subjects, and iii) it is highly enriched in human atherosclerotic 
plaques where it interacts with elastin and enhances macrophage invasion. Moreover, we link a SNP 
near MMP12 that was previously shown to be associated with stroke by Traylor et al. [13] with 
plasma MMP-12 concentrations and mRNA expression of MMP-12, but also with other MMPs in 
carotid plaques. Therefore, the present investigation in combination with the recent article by Traylor 
et al. suggests that MMP-12 may be causally implicated in large-artery stroke. 
We found that three SNPs, rs499459, rs613804 and rs1892971, which are all located in chromosome 
11q22.3 region near the genes MMP1, MMP3, MMP12 and MMP13, were independently associated 
with plasma MMP-12 concentration. No other signals at genome-wide significance were observed in 
our study, although we acknowledge that SNPs outside of chromosome 11q22.3 with smaller effects 
on plasma MMP-12 may still exist. The finding links chromosome 11q22.3 to plasma MMP-12, but 
does not provide conclusive evidence that the associations are mediated via the MMP12 gene itself, as 
other genes in the region may also play a role in determining the plasma MMP-12 concentration. To 
further investigate whether the SNPs associated with plasma MMP-12 levels were specifically 
involved in the regulation of MMP-12 or had effects on neighbouring MMPs too, we performed 
eQTL analyses in carotid plaques. The results revealed that rs1892971 is marginally linked to MMP-
12 mRNA expression, whereas rs499459 is an eQTL also for MMP-1 and MMP-3. Based on the LD 
analysis and the eQTL results, one may speculate that rs1892971 is more distinctly related to the 
MMP12 gene whereas rs499459 and SNPs in LD such as rs660599 may influence a broader set of 
MMPs in the region. Analysis also indicated that rs499459 and rs660599 variants may have the 
potential to highlight a subgroup of patients that are clinically silent at the time of surgery 
(asymptomatic), but that may confer a higher risk of stroke, based on association with MMP-12 
expression in their plaques. 
In the IMPROVE study, we showed that increased plasma MMP-12 concentration at baseline was 
robustly associated to baseline cIMT. This result is well in line with the previous report by Goncalves 
et al. In addition, we observed that plasma MMP-12 at baseline predicted a higher rate of cIMT 
change over time, regardless of the baseline cIMT, and an increased risk of suffering a 
cerebrovascular event within 36 months from baseline. We noted that the association of plasma 
MMP-12 with prospective CVD events was attenuated by adjustment for Framingham risk score 
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parameters, which implies that MMP-12 in plasma reflects presence of one or several of the 
Framingham score risk factors. Indeed, positive correlations between plasma MMP-12 and systolic 
blood pressure, high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol 
(LDL-C) have previously been reported [10], which limits the implications of the reported association 
of plasma MMP-12 with cIMT progression for CHD. Importantly, since MMP-12 concentrations 
measured with our plasma assay may not necessarily reflect the proteinase activity of MMP-12, we 
addressed this issue by a complementary experiment where we confirmed that subjects with higher 
plasma MMP-12 concentrations showed an overall higher concentration of the elastin degradation 
product desmosin.  
We also assessed MMP-12 expression in a large biobank of human carotid endarterectomy samples 
and found that it was strongly enriched at both transriptomic and proteomic levels in plaques 
compared to undiseased arteries, as well as in plaques from patients that suffered stroke compared to 
asymptomatic ones, which not only validates but also extends previous publications about MMP-12 
[32]. Regarding the proteomic enrichment of MMP-12 in central vs. distal segments of plaques, these 
areas have been identified as areas of severe plaque complications vs. stable growth respectively. It 
has been recognized that the central part is associated with all components of a complicated lesion 
(fibrous cap, necrotic core, shoulder region) and increased incidence of cap rupture, while the adjacent 
peripheral end was associated with higher SMC content and represents the fibrotic intima [36-38]. 
Taken together with our genetic data, these findings underscore the significance of MMP-12 in 
prevalent as well as incident stroke. 
Interestingly, Scholtes et al. earlier showed that patients having a high proportion of MMP-12 
expressing macrophages in their carotid plaques are more likely to suffer subsequent stroke and MI 
[33]. In our study, MMP-12 protein was localised to macrophages and shown to interact with elastin 
in situ, especially in areas of degraded ECM. It has been previously demonstrated that MMP-12 has 
broad substrate specificity for a range of ECM proteins, including type IV collagen, fibronectin, 
laminin, vitronectin and basement membrane proteins, while potential regulators of MMP-12 in the 
atherosclerotic environment include several pro-atherosclerotic inflammatory cytokines and growth 
factors released by various cells in the atherosclerotic milieu, such as macrophages, smooth muscle 
and endothelial cells [39]. Considering that MMP-12 activates MMP-2 and MMP-3 [40], we suggest 
that besides direct effects, higher expression of MMP-12 could also lead to activation of these other 
MMPs in plaques, which would further increase degradation of the fibrous cap and promote plaque 
instability. Considering that plaque rupture frequently occurs over a macrophage-rich area near the 
shoulder of the plaque [41], it is interesting to hypothesize that macrophages expressing MMP-12 may 
particularly contribute to thinning and rupture of the fibrous cap and subsequent adverse events. It is 
worth noting here that the BiKE cohort comprises only advanced lesions (AHA grade IV and V), and 
therefore cannot provide information about disease progression. Also, the phenotyping of patients 
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based on the presence or absence of cerebral symptoms was likely insufficient to completely exclude 
overlap between symptomatic and asymptomatic groups, since lesions from asymptomatic patients 
may vary in morphological features of plaque instability [27]. In addition, since atherosclerosis 
presents different features in different vascular beds, we limit our findings about MMP-12 to carotid 
arteries.   
Important studies that have helped to expand the understanding of MMP-12 in atherosclerosis were 
published by Liang et al [42], who demonstrated that rabbits overexpressing human MMP-12 in tissue 
macrophages developed more extensive atherosclerosis in large arteries compared to controls, and 
Johnson et al, who showed that a murine specific MMP-12 inhibitor significantly reduced 
atherosclerotic plaque area in Apo-E knockout mice fed a Western diet [43]. The MMP-12 inhibitor 
treatment induced additional beneficial changes, such as attenuated macrophage invasion and 
apoptosis. Our in vitro results support the notion that MMP-12 influences macrophage invasion, as we 
were able to validate these previous studies by showing markedly decreased migration through the 
ECM upon MMP-12 suppression [34]. Moreover, we demonstrated that MMP-12 suppression not 
only attenuated macrophage invasion, but also reduced the recruitment of other macrophages. One 
may speculate that the invasion-promoting effects of MMP-12 contribute to a vicious cycle where the 
rate of new macrophage recruitment into plaques is amplified by increased production of MMP-12 in 
plaque macrophages and a systemic release of MMP-12 to the circulation. Therefore, suppression of 
MMP-12 could promote double protective effects on the progression of disease: in reducing the 
invasion capacity of macrophages and prohibiting further macrophage recruitment, as well as in 
ameliorating the overall inflammation. One limitation of our invasion assay with the secondary 
macrophage migration setup could be the degradation level of the ECM coating for the newly 
invading macrophages. This could be dependent not only on the primary macrophages in the culture 
(control or siMMP-12), but also the number of the available cells. Thus, a less degraded ECM present 
in the control macrophage culture might provide an easier access for migration and affect the 
secondary invasion rate. However, these effects are likely to be reflective of the pathophysiological 
situation in plaques as well, and in vitro may be considered less significant due to the presence of 
potent chemo-attracting properties of the medium environment in the bottom well.  
Altogether, in the present study we show that MMP-12 transcriptomic and proteomic levels are 
strongly significantly increased in plaques compared with control tissue and in plaques from 
symptomatic vs. asymptomatic patients. MMP-12 localises to CD68+ macrophages in plaques, where 
it interacts with elastin and its silencing results in reduced macrophage migration. These studies 
clearly link higher MMP-12 mRNA and protein levels in plaques to increased atherosclerotic disease. 
In contrast, it appears that genetically lower plasma MMP-12 is significantly associated with 
increased cIMT measurements and risk of stroke. Our study does not aim to disentangle this 
seemingly complex relationship, but as one potential explanation we suggest is the locus pleiotropy, 
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as it is possible that the MMP12 SNPs (in addition to plasma MMP-12) are also associated with other 
yet unknown factors, which may be responsible for their observed protective effects. It may also be 
that MMP-12 expression has differential effects during early atherogenesis compared to advanced 
stages, and even the differential local vs. systemic effects should be taken into account. We speculate 
that plasma MMP-12 may have a protective function, which it can exert on the growing plaque in the 
vasculature by ’surveying’ and minimizing the plaque deposits especially during early atherogenesis, 
while the MMP-12 secreted by macrophages within the late stage plaques degrades the tissue 
rendering it more prone to rupture.  
Despite encouraging pre-clinical data, the design and development of selective MMP inhibitors for 
therapeutic use in CVD still remains at an early stage. The failure of the first generation of broad-
spectrum inhibitors undermined continued evaluation of MMPs as disease targets, and the main focus 
recently has been to design inhibitors targeting detrimental MMPs, without interfering with those that 
have an important role in preventing the progression of disease [44]. To achieve this, a greater 
understanding of the general MMP functions remains essential, including potential differences in how 
MMP-12 particularly contributes to carotid vs. coronary vascular disease. In conclusion, our study 
strengthens the support for MMP-12 as a causal factor in large-artery atherosclerotic stroke and 
highlights its role in macrophage invasion and elastin degradation. 
Conflict of Interest Disclosures 
AM is employed by Pfizer and holds stock in Pfizer Inc. None of the other authors have disclosures to 
report.  
Acknowledgments 
IMPROVE was supported by the European Commission (Contract number: QLG1-CT-2002-00896), 
the Swedish Heart-Lung Foundation, the Swedish Research Council (projects 8691 and 0593), the 
Knut and Alice Wallenberg Foundation, the Foundation for Strategic Research, the Stockholm County 
Council (project 592229), the Strategic Cardiovascular and Diabetes Programmes of Karolinska 
Institutet and Stockholm County Council, the European Union Framework Programme 7 (FP7/2007-
2013) for the Innovative Medicine Initiative under grant agreement n° IMI/115006 (the SUMMIT 
consortium), the Academy of Finland (Grant #110413), the British Heart Foundation (RG2008/08, 
RG2008/014) and the Italian Ministry of Health (Ricerca Corrente). The SNP Technology Platform is 
supported by Uppsala University, Uppsala University Hospital and the Swedish Research Council for 
Infrastructures. The BiKE study was conducted with support from the Swedish Heart and Lung 
Foundation, the Swedish Research Council (K2009-65X-2233-01-3, K2013-65X-06816-30-4 and 
349-2007-8703), Uppdrag Besegra Stroke (P581/2011-123), the Strategic Cardiovascular Programs of 
Page 23 of 52 Journal of Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
16 
 
Karolinska Institutet and Stockholm County Council, the Stockholm County Council (ALF2011-0260 
and ALF-2011-0279), the Foundation for Strategic Research and the European Commission 
(CarTarDis, AtheroRemo, VIA and AtheroFlux projects). Ljubica Perisic Matic is the recipient of 
fellowships from the Swedish Society for Medical Research (SSMF) and Heart and Lung Foundation. 
 
 
 
  
Page 24 of 52Journal of Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
17 
 
REFERENCES 
1 Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of 
atherosclerosis. Nature 2011; 473: 317-25. 
2 Libby P. How does lipid lowering prevent coronary events? New insights from human imaging 
trials. Eur Heart J 2015; 36: 472-4. 
3 Takawale A, Sakamuri SS, Kassiri Z. Extracellular matrix communication and turnover in cardiac 
physiology and pathology. Compr Physiol 2015; 5: 687-719. 
4 Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy 
for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6: 480-98. 
5 Lin J, Kakkar V, Lu X. Impact of matrix metalloproteinases on atherosclerosis. Curr Drug Targets 
2014; 15: 442-53. 
6 Newby AC. Proteinases and plaque rupture: unblocking the road to translation. Curr Opin Lipidol 
2014; 25: 358-66. 
7 Jefferis BJ, Whincup P, Welsh P, et al. Prospective study of matrix metalloproteinase-9 and risk of 
myocardial infarction and stroke in older men and women. Atherosclerosis 2010; 208: 557-63. 
8 Tuomainen AM, Nyyssonen K, Laukkanen JA, et al. Serum matrix metalloproteinase-8 
concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol 
2007; 27: 2722-8. 
9 Velagaleti RS, Gona P, Sundstrom J, et al. Relations of biomarkers of extracellular matrix 
remodeling to incident cardiovascular events and mortality. Arterioscler Thromb Vasc Biol 2010; 30: 
2283-8. 
10 Goncalves I, Bengtsson E, Colhoun HM, et al. Ele ated Plasma Levels of MMP-12 Are 
Associated With Atherosclerotic Burden and Symptomatic Cardiovascular Disease in Subjects With 
Type 2 Diabetes. Arterioscler Thromb Vasc Biol 2015; 35: 1723-31. 
11 Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk 
populations. N Engl J Med 2009; 361: 2599-608. 
12 Cho MH, McDonald ML, Zhou X, et al. Risk loci for chronic obstructive pulmonary disease: a 
genome-wide association study and meta-analysis. Lancet Respir Med 2014; 2: 214-25. 
13 Traylor M, Makela KM, Kilarski LL, et al. A novel MMP12 locus is associated with large artery 
atherosclerotic stroke using a genome-wide age-at-onset informed approach. PLoS Genet 2014; 10: 
e1004469. 
14 Baldassarre D, Veglia F, Hamsten A, et al. Progression of carotid intima-media thickness as 
predictor of vascular events: results from the IMPROVE study. Arterioscler Thromb Vasc Biol 2013; 
33: 2273-9. 
15 Baldassarre D, Hamsten A, Veglia F, et al. Measurements of carotid intima-media thickness and of 
interadventitia common carotid diameter improve prediction of cardiovascular events: results of the 
Page 25 of 52 Journal of Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
18 
 
IMPROVE (Carotid Intima Media Thickness [IMT] and IMT-Progression as Predictors of Vascular 
Events in a High Risk European Population) study. J Am Coll Cardiol 2012; 60: 1489-99. 
16 Assarsson E, Lundberg M, Holmquist G, et al. Homogenous 96-plex PEA immunoassay exhibiting 
high sensitivity, specificity, and excellent scalability. PLoS One 2014; 9: e95192. 
17 Gertow K, Sennblad B, Strawbridge RJ, et al. Identification of the BCAR1-CFDP1-TMEM170A 
locus as a determinant of carotid intima-media thickness and coronary artery disease risk. Circ 
Cardiovasc Genet 2012; 5: 656-65. 
18 Cortes A, Brown MA. Promise and pitfalls of the Immunochip. Arthritis Res Ther 2011; 13: 101. 
19 Rothwell PM, Pendlebury ST, Wardlaw J, Warlow CP. Critical appraisal of the design and 
reporting of studies of imaging and measurement of carotid stenosis. Stroke 2000; 31: 1444-50. 
20 Halliday A, Harrison M, Hayter E, et al. 10-year stroke prevention after successful carotid 
endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet 2010; 
376: 1074-84. 
21 Perisic Matic L, Rykaczewska U, Razuvaev A, et al. Phenotypic Modulation of Smooth Muscle 
Cells in Atherosclerosis Is Associated With Downregulation of LMOD1, SYNPO2, PDLIM7, PLN, 
and SYNM. Arterioscler Thromb Vasc Biol 2016; 36: 1947-61. 
22 Di Taranto MD, Morgante A, Bracale UM, et al. Altered expression of inflammation-related genes 
in human carotid atherosclerotic plaques. Atherosclerosis 2012; 220: 93-101. 
23 Papaspyridonos M, Smith A, Burnand KG, et al. Novel candidate genes in unstable areas of human 
atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2006; 26: 1837-44. 
24 Folkersen L, Persson J, Ekstrand J, et al. Prediction of ischemic events on the basis of 
transcriptomic and genomic profiling in patients undergoing carotid endarterectomy. Mol Med 2012; 
18: 669-75. 
25 Razuvaev A, Ekstrand J, Folkersen L, et al. Correlations between clinical variables and gene-
expression profiles in carotid plaque instability. Eur J Vasc Endovasc Surg 2011; 42: 722-30. 
26 Perisic L, Hedin E, Razuvaev A, et al. Profiling of atherosclerotic lesions by gene and tissue 
microarrays reveals PCSK6 as a novel protease in unstable carotid atherosclerosis. Arterioscler 
Thromb Vasc Biol 2013; 33: 2432-43. 
27 Perisic L, Aldi S, Sun Y, et al. Gene expression signatures, pathways and networks in carotid 
atherosclerosis. J Intern Med 2016; 279: 293-308. 
28 Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev 
Cardiol 2014; 11: 276-89. 
29 Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE, 3rd. 
Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. 
TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41. 
30 Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: 
rising to the challenge of larger and richer datasets. Gigascience 2015; 4: 7. 
Page 26 of 52Journal of Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
19 
 
31 Arnold M, Raffler J, Pfeufer A, Suhre K, Kastenmuller G. SNiPA: an interactive, genetic variant-
centered annotation browser. Bioinformatics 2015; 31: 1334-6. 
32 Halpert I, Sires UI, Roby JD, et al. Matrilysin is expressed by lipid-laden macrophages at sites of 
potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a 
proteoglycan substrate for the enzyme. Proc Natl Acad Sci U S A 1996; 93: 9748-53. 
33 Scholtes VP, Johnson JL, Jenkins N, et al. Carotid atherosclerotic plaque matrix metalloproteinase-
12-positive macrophage subpopulation predicts adverse outcome after endarterectomy. J Am Heart 
Assoc 2012; 1: e001040. 
34 Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro SD. Metalloelastase is required 
for macrophage-mediated proteolysis and matrix invasion in mice. Proceedings of the National 
Academy of Sciences of the United States of America 1996; 93: 3942-6. 
35 Matsumoto S, Kobayashi T, Katoh M, et al. Expression and localization of matrix 
metalloproteinase-12 in the aorta of cholesterol-fed rabbits: relationship to lesion development. Am J 
Pathol 1998; 153: 109-19. 
36 Cicha I, Worner A, Urschel K, et al. Carotid plaque vulnerability: a positive feedback between 
hemodynamic and biochemical mechanisms. Stroke 2011; 42: 3502-10. 
37 Yang C, Canton G, Yuan C, Ferguson M, Hatsukami TS, Tang D. Advanced human carotid plaque 
progression correlates positively with flow shear stress using follow-up scan data: an in vivo MRI 
multi-patient 3D FSI study. J Biomech 2010; 43: 2530-8. 
38 Fagerberg B, Ryndel M, Kjelldahl J, et al. Differences in lesion severity and cellular composition 
between in vivo assessed upstream and downstream sides of human symptomatic carotid 
atherosclerotic plaques. J Vasc Res 2010; 47: 221-30. 
39 Feinberg MW, Jain MK, Werner F, et al. Transforming growth factor-beta 1 inhibits cytokine-
mediated induction of human metalloelastase in macrophages. J Biol Chem 2000; 275: 25766-73. 
40 Shapiro SD, Kobayashi DK, Ley TJ. Cloning and characterization of a unique elastolytic 
metalloproteinase produced by human alveolar macrophages. Journal of Biological Chemistry 1993; 
268: 23824-9. 
41 Libby P, Geng YJ, Aikawa M, et al. Macrophages and atherosclerotic plaque stability. Current 
Opinion in Lipidology 1996; 7: 330-5. 
42 Liang J, Liu E, Yu Y, et al. Macrophage metalloelastase accelerates the progression of 
atherosclerosis in transgenic rabbits. Circulation 2006; 113: 1993-2001. 
43 Johnson JL, Devel L, Czarny B, et al. A selective matrix metalloproteinase-12 inhibitor retards 
atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc 
Biol 2011; 31: 528-35. 
44 Amar S, Fields GB. Potential clinical implications of recent matrix metalloproteinase inhibitor 
design strategies. Expert Rev Proteomics 2015: 1-3. 
Page 27 of 52 Journal of Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
20 
 
 
CORRESPONDING AUTHOR 
Anders Mälarstig, PhD 
Address: Centre for Molecular Medicine, L8:02 
Karolinska Institute  
171 76 Stockholm, Sweden 
Email: anders.malarstig@ki.se, anders.malarstig@pfizer.com  
Telephone: +46 8 55052514 
 
 
 
 
  
Page 28 of 52Journal of Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
21 
 
TABLE AND FIGURE LEGENDS 
 
Fig 1. Flow-chart of the study cohorts and design. Analyses of plasma MMP-12 concentrations in 
relation to cIMT progression, future CVD events and SNPs were conducted in the IMPROVE study, 
which recruited 3,397 subjects with high CVD risk but without manifest CVD at baseline. These 
investigations were followed by eQTL analyses of the associated SNPs in relation to MMP-12 mRNA 
expression in atherosclerotic plaque specimens from 127 patients undergoing carotid endarterectomy 
in the BiKE study. Furthermore, MMP-12 mRNA and protein expression levels were examined in 
atherosclerotic plaques compared to control tissues (non-atherosclerotic arteries or adjacent distal 
plaque tissue). Finally, MMP-12 protein localisation, activity and interaction with elastin and the 
effects of MMP-12 silencing were investigated using molecular biology methods in plaques, plasma 
and functional assays in vitro.  
Table 1. Association of plasma MMP-12 and Framingham risk parameters. Partial correlations 
with correction for study recruitment site were calculated to assess the relationship between plasma 
MMP-12 and Framingham score parameters. R indicates the correlation coefficient. 
Table 2. Association of plasma MMP-12 with baseline cIMT. CCA indicates common carotid 
artery, standardised beta indicates the standard deviation change per standard deviation of the cIMT 
measure. R2 model indicates the variability explained by linear regression model adjusted for age, 
gender, smoking, total cholesterol, HDL cholesterol, diabetes, systolic blood pressure and study 
centre. 
Table 3. Association of Framingham score parameters and plasma MMP-12 with cIMT 
progression. cIMT progression was defined as previously described (Baldassarre D et al. J Am Coll 
Cardiol 2012; 60: 1489-99.). The left side of the Table shows correlation coefficients and p-values for 
single-parameter correlations with correction only for study site. The right side of the Table shows 
results from a multiple linear regression model that included all parameters shown. The beta-values 
are given as standard deviation per standard deviation of cIMT progression.  
Fig 2. eQTL analysis of MMP12 associated SNPs in atherosclerotic plaques. MMP12 variant 
rs1892971 was found to be tentatively associated to MMP-12 mRNA expression in carotid plaques. 
This variant was also un-associated to the expression of other MMPs from the same locus in plaques 
(A). Variant rs566125 was strongly associated to the expression levels of MMP-1 and marginally also 
MMP-3 and MMP-13, but not MMP-12 (B). SNP rs615098 (a perfect proxy for METASTROKE 
MMP12 associated variant rs660599) was marginally associated to MMP-12 expression in plaques, 
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and significantly to the expression of both MMP-1 and MMP-3 (C). Plots show median±standard 
deviation (SD).  
Fig 3. Expression analyses of MMP-12 in carotid plaques. MMP-12 mRNA is upregulated in 
plaques (cp) compared with normal arteries (na) and in plaques extracted from symptomatic (s) 
compared with asymptomatic (as) patients. Plots show log2 mean±SD (upper panels). Similarly, 
MMP-12 protein levels are enriched in plaques compared with adjacent arterial tissue, and in plaques 
from symptomatic vs. asymptomatic patients. Plots show mean relative levels with SD (A). MMP-12 
transcript and protein are significantly correlated with macrophage markers (CD163, CD36 and 
MAC2) in BiKE plaques (B). 
Fig 4. Localisation of MMP-12 in plaques. In the normal artery no MMP12 immunoreactivity was 
detected, while elastin (green signal) was abundant in the media (A, arrows). In consecutive plaque 
sections (B), MMP-12 was localised to the CD68
+ 
macrophage-rich regions in the necrotic core (third 
panel, arrows and enlarged inset). Intact elastin fibres were present at the periphery of the plaques 
(middle panel, green staining, arrows) where no MMP-12 (red signal) was expressed, but they 
appeared gradually disarranged closer towards the necrotic core where MMP-12 was enriched 
(enlarged inset). By proximity ligation assay (PLA) in consecutive plaque sections, positive signal for 
MMP-12 and elastin co-interacting proteins was detected (enlarged inset, middle panel), specifically 
in regions with moderate to strong MMP-12 expression (C). As positive control PLA probe directed 
to MMP-12 antibody was used, showing areas of intense MMP-12 expression in the necrotic core 
(arrows, third panel). No PLA signal was observed in the negative control (enlarged inset, first panel). 
Fig. 5. MMP-12 RNA silencing and antibody blocking reduce macrophage migration. Panel in A 
(left) shows THP-1 derived macrophages migrated through a Transwell chamber without bottom 
coating. Middle panel shows macrophages migrated through a Transwell with MaxGel coating. Right 
panel shows macrophages incubated with 0.25mg MMP-12 antibody prior to migration through a 
Transwell with MaxGel coating. All chambers had 8mm diameter holes at the bottom of the top 
Transwell, cells were stained with the nuclear stain DAPI (blue). In (B) macrophage nuclei stained red 
(DRAQ5) represent the primary invaded cells in control or siMMP12 conditions, while macrophage 
nuclei in blue (DAPI) represent the migrated cells in both conditions. Purple coloured nuclei are those 
double stained for DRAQ5/DAPI. On average, 70% (±16.2% SD, p=0.011) more macrophages 
migrated towards the control macrophages than towards siMMP12 macrophages. The quantification is 
represented as a bar graph in the last panel.  
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FIGURES AND TABLES 
 
Figure 1.  
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Table 1.  
 
  Plasma MMP-12 
  R P-value 
Age 0.24 8.7E-45 
Female gender -0.03 0.097 
Smoking 0.19 4.2E-29 
Total cholesterol (mmol/L) 0.01 0.633 
HDL cholesterol (mmol/L) -0.13 9.3E-15 
Diabetes 0.05 0.002 
Systolic blood pressure (mm Hg) 0.04 0.024 
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Table 2.  
 
 
 
  Standardised beta p-value R2 model 
Mean CCA IMT .091 5.6E-08 0.190 
Mean Bulb IMT .088 3.3E-07 0.151 
Mean IMT .112 5.4E-12 0.242 
Max IMT .100 6.9E-09 0.155 
Plaque area .099 5.4E-10 0.268 
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Table 3.  
 
 
 Correlations 
 
Multiple Linear Regression 
  R2 p-value 
 Standardised 
Beta 
p-value 
Age 0.04 0.027  0.069 0.001 
Female gender -0.08 2.0E-05  -0.074 2.0E-05 
Smoking 0.07 3.1E-04  0.038 0.042 
Total cholesterol (mmol/L) 0.04 0.021  0.053 0.008 
HDL cholesterol (mmol/L) 0.02 0.297  -0.052 0.011 
Diabetes -0.07 2.9E-04  0.038 0.051 
Systolic blood pressure (mm Hg) 0.06 1.6E-03  0.042 0.04 
Plasma MMP-12 (arbitrary units) 0.11 1.1E-09  0.074 5.0E-05 
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Figure 2.  
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Figure 3.  
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Figure 4.  
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Figure 5.  
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Supplemental Materials and Methods 
Proteomic analysis of plaques 
Atherosclerotic plaques from n=18 BiKE patients (n=9 symptomatic + 9 asymptomatic; 
matched for male gender, age and statin medication) were analysed using LC-MS/MS as 
previously described 1. Briefly, protein samples were digested by trypsin and the resulting 
tryptic peptides were TMT-labeled and pooled. Pooled samples were cleaned by Strong 
Cation exchange columns (Phenomenex) and subjected to LC-MS/MS analysis. The sample 
pools were separated on a 4 hour gradient using an UPLC-system (Dionex UltiMate™ 3000) 
coupled to a Q-Exactive mass spectrometer (Thermo Fischer Scientific, San Jose, CA, USA). 
The fragment spectra from the mass spectrometer were matched to a database consisting of 
theoretical fragment spectra from all human proteins and filtered at a 1% False Discovery 
Rate on the peptide level to obtain protein identities (Uniprot). Quantitative information was 
acquired by using the TMT reporter ion intensities. 
Immunohistochemistry (IHC)  
All IHC reagents were from Biocare Medical (Concord, CA). Isotype rabbit and mouse IgG 
were used as negative controls. In brief, 5 µm sections were deparaffinized in Tissue Clear 
and rehydrated in an ethanol series. For antigen retrieval, slides were subjected to high-
pressure boiling in DIVA buffer (pH 6.0). After blocking with Background Sniper, primary 
antibodies: total MMP-12 (ab66157, Abcam), elastin (ab77804, Abcam), active MMP-12 
(ab38908) and CD68 (ncl-1-cd68, Novocastra) were diluted in Da Vinci Green solution, 
applied on slides and incubated at room temperature for 1 hour. A double-stain probe-
polymer system containing alkaline phosphatase and horseradish peroxidase was applied, 
with subsequent detection using Warp Red and Vina Green. Slides were counterstained with 
Hematoxylin QS (Vector Laboratories, Burlingame, CA), dehydrated and mounted in Pertex 
(Histolab, Gothenburg, Sweden). Images were taken using a Nikon OPTIPHOT-2 microscope 
equipped with a digital camera and processed with NIS-Elements software. 
Proximity Ligation Assay (PLA) 
Plaque slides were first de-paraffinized in Tissue Clear and rehydrated in an ethanol series. 
For antigen retrieval, slides were subjected to high-pressure boiling for 10 min in DIVA 
buffer (pH 6.0). After blocking with Background Sniper, primary antibodies against MMP-12 
(ab66157, Abcam) and elastin (ab77804, Abcam) were diluted in Da Vinci Green solution, 
applied on slides and incubated at +4C overnight in a humid chamber. PLA probe ligation and 
amplification steps were performed using Duolink In Situ Detection Brightfield kit (DUO 
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92012, Sigma-Aldrich), following manufacturer’s instructions. Thereafter, slides were 
rehydrated in ethanol series and mounted for visualization.  
Cell Culture  
Human monocyte leukaemia cell line THP1 (ATCC Cat. No. TIB-202) was grown in 
suspension at 37°C in a humidified 5% CO2 incubator in RPMI (Gibco, Life Technologies) 
medium supplemented with 2mM L-Glutamine, 10% FBS, 50 U/mL penicillin, and 50 µg/mL 
streptomycin. THP1 cells were seeded at 3.5 106 densities into polystyrene treated 20 mm 
Falcon cell culture disposable dishes (Corning) and differentiated into macrophage-like cells 
by addition of PMA to a final concentration of 50 ng/ml for 72h 2, 3. TransIT-siQuest (Mirus 
Bio LLC) was used as transfection reagent. siRNA oligonucleotides specific for MMP-12 
(catalogue no. s8873) and scramble siRNA used as negative control were purchased from 
Ambion (Life Technologies). Silencing was performed at a cell density of around 3.5 to 4 
x106 cells per Petri dish in 10 ml complete RPMI medium, 0.4 nmol of MMP-12 siRNA was 
used with 20 µl TransIT-siQuest reagent. The dishes were incubated at 37°C in a humidified 
5% CO2 incubator for 24 hours.  
Validation of MMP-12 silencing by siRNA 
Silencing efficacy was measured with quantitative PCR and Western blot.  PCR amplification 
was performed in 96-well plates in 7900 HT real-time PCR system (Applied Biosystems), 
using TaqMan® Universal PCR Master Mix (Applied Biosystems) and TaqMan® Gene 
Expression Assays (Hs00899662_m1 for measuring MMP-12 expression). All samples were 
measured in triplicates. Results were normalized to the equal mass of total RNA as well as the 
Ct values of RPLPO internal control (probe Hs99999902_m1). The relative amount of target 
gene mRNA was calculated by 2 (-∆∆Ct) method. For Western blot, proteins were extracted 
using RIPA buffer on ice. Samples were reduced with β-mercaptoethanol and heated to 95ºC 
for 10 minutes. Proteins were separated using Mini-Protean® TGX™ Precast Gels 4-20% 
(BIORAD) and transferred to Immun-Blot® PVDF membrane (BIORAD) for 1h. Primary 
and secondary antibodies were added to the membranes in recommended dilutions.  
Invasion and migration assays 
For invasion assay, polycarbonate membrane cell culture inserts (ID: CLS3422, Sigma 
Aldrich, Corning® Transwell®) with 8 µm pores were coated with MaxGel ECM (final 
concentration 0.1 mg/ml, catalog no. E0282 Sigma-Aldrich) for 2 hours at 37°C in a 
humidified 5% CO2 incubator. Macrophages at density of 1.5 x 10
5 cells in 500µl medium 
were added to the polycarbonate well inserts, inserts transferred to the 24-well plate and 
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incubated for 22 hours. For migration assays, cells were washed and stained with DRAQ5 in 
Petri dishes for 10 minutes in dark. The staining solution was removed and the cells washed 
twice with PBS. Macrophages were then detached by adding 1ml Cellstripper non-enzymatic 
solution (Corning) to the Petri dishes. The cells were collected and centrifuged for 5 minutes 
at 1000 rpm, cell pellet was diluted with serum free RPMI medium and 1.5 x 105 cells in 500 
µl medium were added to the inserts which were previously invaded with either siMMP-12 or 
scramble transfected macrophages.  
Fluorescent stainings 
The medium in the insert wells was aspirated and the wells were washed twice with PBS and 
placed in clean wells. 200 and 500µl DAPI (0.5 µg/ml in PBS) was added to the upper 
respective lower wells and incubated for 5 minutes in dark. Non-invaded cells from the top of 
the insert wells were scraped off by cotton swabs. For the macrophage invasion staining, cells 
were stained with DRAQ5 at final concentration of 5µM in PBS for 20 minutes in dark. 
Images were obtained using a reversed Leica SP5 confocal microscope, equipped with a 20 × 
1.4 lens and diode and Helium lasers. Images were processed using ImageJ software.   
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Supplemental Figures and Tables 
 
Supplementary Fig I  
 
Plasma MMP-12, adjustments 
Odds ratio, 95 
% confidence 
interval 
P-value 
Plasma MMP-12 tertiles adjusted for age, gender and 
site 
1.45 (1.06-1.99) 0.022 
Plasma MMP-12 tertiles adjusted for site, age, 
gender, smoking, diabetes, total cholesterol, HDL-C 
and systolic blood pressure 
1.26 (0.92-1.773) 0.15 
 
Supplementary Fig I. Cumulative hazard curves of cerebrovascular events for MMP-12 
tertiles in the IMPROVE study analysed using Cox-regression with adjustment for site, age 
and gender. A total of 67 cerebrovascular events occurred in IMPROVE during the 36-month 
follow-up, n=14 in lower and n=33 in higher tertiles, respectively. 
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Supplementary Fig II 
 
 
 
 
 
Supplementary Fig II. Manhattan plot and regional plot for association of plasma MMP-12 
in the IMPROVE study. 
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Supplementary Table I 
 
 
 
    
Plasma MMP-12 
 
Plasma MMP-12, p-values from 
conditional tests 
rs id Position Alleles MAF BETA SE P Nearest Gene rs499459 rs1892971 rs613804 
rs499459 102,693,186 A,G 18.3% -0.565 0.030 8.26E-76 
MMP1,  
MMP3 NaN 4.56E-66 1.36E-70 
rs655403 102,708,507 C,T 18.5% -0.538 0.029 5.70E-72 MMP3 3.49E-01 1.93E-63 6.32E-67 
rs660599           
rs1892971 102,795,606 A,G 25.9% 0.304 0.027 7.97E-29 
MMP12(dist=49842),  
MMP13(dist=18115) 4.94E-19 NaN 6.67E-36 
rs671188 102,829,455 C,T 43.9% -0.234 0.024 1.02E-21 
MMP13,  
DCUN1D5 1.45E-04 2.07E-09 7.33E-27 
rs2186789 102,911,494 G,T 23.9% -0.247 0.028 4.98E-18 
MMP13(dist=85031),  
DCUN1D5(dist=9919) 2.30E-03 4.32E-10 3.05E-18 
rs1144397 102,682,285 G,T 44.9% -0.207 0.024 1.28E-17 
MMP1,  
MMP3 1.78E-01 9.85E-08 3.03E-27 
rs613804 102,720,421 C,T 5.7% 0.415 0.053 3.80E-15 
MMP3(dist=6079),  
MMP12(dist=13043) 7.33E-10 2.88E-22 NaN 
rs501371 102,748,450 A,G 5.9% 0.398 0.052 2.24E-14 
MMP12(dist=2686),  
MMP13(dist=65271) 2.49E-09 1.46E-21 4.18E-01 
rs1277718 102,747,551 C,G 5.9% 0.398 0.052 2.33E-14 
MMP12(dist=1787),  
MMP13(dist=66170) 2.59E-09 1.58E-21 4.18E-01 
rs1942524 102,838,300 C,T 26.8% 0.175 0.027 1.38E-10 
MMP13(dist=11837), 
 DCUN1D5(dist=83113) 9.89E-06 8.05E-07 9.93E-12 
rs484915 102,673,248 A,T 41.4% 0.148 0.024 1.65E-09 
MMP1(dist=4282), 
MMP3(dist=33280) 4.74E-01 3.30E-06 5.35E-14 
rs650108 102,708,787 A,G 25.3% 0.163 0.028 5.39E-09 MMP3 2.15E-01 5.89E-22 2.18E-03 
 
 
 
Supplementary Table I. SNPs associated with plasma MMP-12 at genome-wide 
significance with and without conditioning on lead SNPs. 
  
Page 45 of 52 Journal of Internal Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Supplementary Table II 
 
 
 
 
 
 
 
Supplementary Table II. Linkage disequilibrium between the SNPs identified in the present 
study and the lead SNP for large-artery stroke. 
 
 
  
SNP Lead SNP stroke Distance (bp) LD r² LD D' MAF 
rs499459 rs660599 -36,571 0.44 -0.77 18.1 % 
rs613804 rs660599 9,336 0.28 1 5.7 % 
rs1892971 rs660599 65,849 <0.01 0.1 25.9 % 
 rs660599 0 1 1 21.0 % 
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Supplementary Table III 
 
 
 
 
n Plasma MMP-12 Mean IMT Max IMT Plaque area 
   
Mean SD Mean SD Mean SD Mean SD 
rs660599 A A 133 6.66 0.83 0.95 0.21 2.27 0.91 97.78 57.57 
 
A G 1190 6.98 0.73 0.9 0.2 2.12 0.86 89.71 54.37 
 
G G 2143 7.22 0.66 0.88 0.2 1.97 0.77 85.21 53.78 
p-value, ANOVA trend 8.8E-35 
 
1.2E-04 
 
6.0E-08 
 
0.01 
 
rs1892971 A A 237 7.39 0.66 0.9 0.21 1.99 0.8 89.09 55.4 
 
A G 1316 7.21 0.68 0.88 0.2 1.99 0.78 86.11 54.29 
 
G G 1913 7.02 0.71 0.89 0.2 2.07 0.83 87.78 54 
p-value, ANOVA trend 7.8E-29 
 
0.05 
 
1.3E-04 
 
0.12 
 
rs499459 A A 115 6.41 0.79 0.95 0.21 2.3 0.91 102.56 58.35 
 
A G 1037 6.9 0.7 0.91 0.2 2.15 0.87 93.42 53.97 
 
G G 2314 7.25 0.66 0.88 0.2 1.97 0.77 83.69 53.73 
p-value, ANOVA trend 3.6E-66 
 
8.5E-04 
 
2.1E-05 
 
8.0E-03 
 
rs613804 A A 6 7.33 0.58 -0.08 0.09 0.30 0.14 59.56 36.47 
 
A G 379 7.37 0.68 -0.06 0.09 0.28 0.16 83.51 53.02 
 
G G 3059 7.09 0.70 -0.06 0.09 0.28 0.17 87.78 54.38 
p-value, ANOVA trend 3.3E-13 
 
0.34 
 
0.56 
 
0.10 
 
 
 
 
 
Supplementary Table III. Association for each of the main study SNPs with plasma MMP-
12 levels, mean and max cIMT and plaque area, stratified by alleles.  
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Supplementary Fig III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Fig III. eQTL analysis of MMP12 associated variants in atherosclerotic 
plaques, stratified according to the patient phenotype. For rs1892971, none of the 
asymptomatic patients in BiKE could be found with AA genotype. Plots show median with 
min to max whiskers.   
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Supplementary Fig IV 
 
 
 
Supplementary Fig IV. Analysis of the linkage disequilibrium at the MMP12 locus.  
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Supplementary Fig V 
 
 
 
Supplementary Fig V. Additional photomicrographs showing the localization of MMP-12 in 
plaques. MMP-12 (red signal) is strongly expressed by cells in the necrotic core, occasionally 
underlined by the remaining elastin fibres (green staining, enlarged insets) (A). In consecutive 
sections from plaques, total MMP-12 (red signal) was localised to the macrophage-rich 
regions in the necrotic core (B, second panel, arrows). Active MMP-12 (third panel, arrows) 
was observed diffusely in the extracellular matrix of the lesions, especially in regions where 
elastin fibres (fourth panel, arrows) were disarranged or completely absent.  
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Supplementary Fig VI 
 
 
 
 
 
Supplementary Fig VI. Positive association between plasma MMP-12 concentration and 
elastolytic activity (A). Error bars represent mean±standard deviation (SD). Total MMP-12 
protein levels are inversely correlated to elastin levels in plaques (B).  
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Supplementary Fig VII 
 
 
 
 
Supplementary Fig VII. Validation of MMP-12 silencing in vitro. Western blot analysis of 
total and active MMP-12 levels in macrophages treated with MMP-12 siRNA or scramble 
control (left panel). Right panel shows relative MMP-12 mRNA levels quantified by qPCR. 
The values are expressed as fold change compared to control and represent mean±SD of four 
independent experiments. 
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